Abstract
This study was designed to determine the protective effect of melatonin treatment against oxidative damage in rat brain induced by hyperhomocysteinemia (Hhcy). Oral administration of methionine and its degradation product, homocysteine (hcy), causes mild to moderate Hhcy. The major end-point of oxidative damage measured in this report was lipid peroxidation (LPO). The levels of malondialdehyde (MDA) were assayed as index of lipid peroxidation. The increase in lipid peroxidation was inhibited by melatonin. Rats were divided into seven groups: one was used as control and each remaining group was supplemented with methionine dissolved and added to the drinking water daily for 4 weeks (0.5, 1, 1.5, 2, 3g / kg BW). Additional groups of rats were given both melatonin (30 mg / kg BW) and methionine in drinking water daily. At the conclusion of the study, MDA levels were significantly increased in the brains of methioninetreated rats compared with control rats, whereas melatonin prevented the increases in MDA levels. Plasma hcy levels in animals treated with melatonin were significantly lower than those of controls. Melatonin lowered plasma hcy levels and could potentially be beneficial in prevention of neurodegeneration caused by mild hyperhomocysteinemia.
Keywords: hyperhomocysteinemia, homocysteine, methionine, melatonin, lipid, peroxidation, oxidative stress, malondialdeyde
Current Neurovascular Research
Title: Melatonin Prevents Hyperhomocysteinemia and Neural Lipid Peroxidation Induced by Methionine Intake
Volume: 2 Issue: 2
Author(s): Mounir Bouzouf, Francisco Martinez-Cruz, Patrocinio Molinero, Juan M Guerrero and Carmen Osuna
Affiliation:
Keywords: hyperhomocysteinemia, homocysteine, methionine, melatonin, lipid, peroxidation, oxidative stress, malondialdeyde
Abstract: This study was designed to determine the protective effect of melatonin treatment against oxidative damage in rat brain induced by hyperhomocysteinemia (Hhcy). Oral administration of methionine and its degradation product, homocysteine (hcy), causes mild to moderate Hhcy. The major end-point of oxidative damage measured in this report was lipid peroxidation (LPO). The levels of malondialdehyde (MDA) were assayed as index of lipid peroxidation. The increase in lipid peroxidation was inhibited by melatonin. Rats were divided into seven groups: one was used as control and each remaining group was supplemented with methionine dissolved and added to the drinking water daily for 4 weeks (0.5, 1, 1.5, 2, 3g / kg BW). Additional groups of rats were given both melatonin (30 mg / kg BW) and methionine in drinking water daily. At the conclusion of the study, MDA levels were significantly increased in the brains of methioninetreated rats compared with control rats, whereas melatonin prevented the increases in MDA levels. Plasma hcy levels in animals treated with melatonin were significantly lower than those of controls. Melatonin lowered plasma hcy levels and could potentially be beneficial in prevention of neurodegeneration caused by mild hyperhomocysteinemia.
Export Options
About this article
Cite this article as:
Bouzouf Mounir, Martinez-Cruz Francisco, Molinero Patrocinio, Guerrero M Juan and Osuna Carmen, Melatonin Prevents Hyperhomocysteinemia and Neural Lipid Peroxidation Induced by Methionine Intake, Current Neurovascular Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567202053586839
DOI https://dx.doi.org/10.2174/1567202053586839 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome
Current Pharmaceutical Design ACE2 as a Key Target for Treatment of COVID-19 Related Cardiovascular Diseases: Current Progress and Prospect
Current Drug Targets Cervical Cancer Diagnosis: Insights into Biochemical Biomarkers and Imaging Techniques
Combinatorial Chemistry & High Throughput Screening Role of Micronutrients on Subclinical Atherosclerosis Micronutrients in Subclinical Atherosclerosis
Current Pharmaceutical Design Elevated Inflammatory Parameter Levels Negatively Impact Populations of Circulating Stem Cells (CD133+), Early Endothelial Progenitor Cells (CD133+/VEGFR2+), and Fibroblast Growth Factor in Stroke Patients
Current Neurovascular Research Cerebrovascular Complications After Heart Transplantation
Current Cardiology Reviews Immunological Mechanisms of Neuropsychiatric Lupus
Current Immunology Reviews (Discontinued) Medical Treatment of Peripheral Arterial Disease: Current Concepts and Future Options
Vascular Disease Prevention (Discontinued) Combining Diffusion-Weighted Imaging Patterns with ABCD2 Score Predicts Stroke Risk after Transient Ischemic Attack
Current Neurovascular Research What Characterizes Endothelial Dysfunction in Preeclampsia? -The Action of NO and the Production of Prostacyclin is Reduced, While EDHF is Preserved in Omental Resistance Arteries in Preeclamptic Women
Current Women`s Health Reviews Preterm Labour: An Overview of Current and Emerging Therapeutics
Current Medicinal Chemistry Mandatory Reporting of Coronary Artery Calcifications Incidentally Noted on Chest Multi-Detector Computed Tomography: A Multicentre Experience
Current Vascular Pharmacology Viral Disorder or Disordered Viruses: Do Viral Proteins Possess Unique Features?
Protein & Peptide Letters Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Targeting the Akt Kinase to Modulate Survival, Invasiveness and Drug Resistance of Cancer Cells
Current Medicinal Chemistry Biomarkers Determining Cardiovascular Risk in Patients with Kidney Disease
Current Medicinal Chemistry Potential Biomarkers for Depression Associated with Coronary Artery Disease: A Critical Review
Current Molecular Medicine Targeting the Eph System with Peptides and Peptide Conjugates
Current Drug Targets Atenolol: Differences in Mode of Action Compared with other Antihypertensives.An Opportunity to Identify Features that Influence Outcome?
Current Pharmaceutical Design IP6 & Inositol in Cancer Prevention and Therapy
Current Cancer Therapy Reviews